Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling
Clinical Pharmacology & Therapeutics · 2024-09 · 116 (3) · 770-781
DOI: 10.1002/cpt.3273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.05.2024. Verfasst von Robin Thomas Ulrich Haid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Modeling & Simulation, Drug Metabolism & Pharmacokinetics, Preclinical Development, Bayer AG, Berlin, Germany. Hauptthemen laut MEDLINE: Models, Biological, Proteolysis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Targeted protein degraders (TPDs), an emerging therapeutic modality, are attracting considerable interest with the promise to address disease‐related proteins that are not druggable with conventional small molecule inhibitors. Despite their novel mechanism of action, the PK/PD relationship of degraders is still approached with a mindset deeply rooted in inhibitor drugs. Here, we establish how predictive mechanistic modeling specifically tailored to TPDs can significantly enhance the value of the available information during lead generation and optimization. By integrating the results from in vitro assays with routinely collected PK data, modeling accurately predicts degradation in vivo . These predictions transform the prioritization of compounds for in vivo studies as well as the selection of optimal dose schedules and most informative measurement time points with the least number of animals. Moreover, the comprehensive modeling framework (1) identifies the PK/PD driver of targeted protein degradation and subsequent downstream pharmacodynamic effects, and (2) uncovers the fundamental difference between degrader and inhibitor PK/PD relationships. The practical utility of our predictive modeling is demonstrated with relevant use cases. This framework will allow researchers to transition from current, mostly serendipity‐based approaches to more sound model‐informed decision making. Going forward, the presented predictive PK/PD modeling framework lays out a rational path to incorporate inter‐species differences in the pharmacology and thus promises to help with getting the dose right in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Preclinical Modeling & Simulation, Drug Metabolism & Pharmacokinetics, Preclinical Development, Bayer AG, Berlin, Germany.
- Biopharmacy, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
ORCID-Profile: Robin Thomas Ulrich Haid, Andreas Reichel
Zitieren
APA
Haid, R. T. U., & Reichel, A. (2024). Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling. Clinical Pharmacology & Therapeutics, 116(3), 770-781. https://doi.org/10.1002/cpt.3273
Vancouver
Haid RTU, Reichel A. Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling. Clinical Pharmacology & Therapeutics. 2024;116(3):770-781. doi:10.1002/cpt.3273
BibTeX
@article{Haid2024,
author = {Haid, Robin Thomas Ulrich and Reichel, Andreas},
title = {Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {3},
pages = {770--781},
doi = {10.1002/cpt.3273}
}
EUVIMED